Absence of IgG antibodies among high-risk contacts of two confirmed cases of Crimean-Congo haemorrhagic fever in the autonomous region of Madrid (Spain).


Journal

Journal of infection and public health
ISSN: 1876-035X
Titre abrégé: J Infect Public Health
Pays: England
ID NLM: 101487384

Informations de publication

Date de publication:
Oct 2020
Historique:
received: 15 05 2019
revised: 08 07 2020
accepted: 22 07 2020
pubmed: 24 8 2020
medline: 28 4 2021
entrez: 24 8 2020
Statut: ppublish

Résumé

Crimean-Congo haemorrhagic fever (CCHF) is a widely distributed tick-borne disease. In Spain, the disease has emerged as outbreak associated with high-risk exposures. Our goal was to evaluate the prevalence of antibodies against the CCHF virus (CCHFV) in high-risk contacts. A cross-sectional study was conducted. Three hundred eighty-six high-risk contacts were identified comprising family contacts and hospital workers who had attended the cases. Fifty-seven cases with closer exposure were selected. However, forty-nine cases participated in the study. IgG antibodies were detected by immunoenzymatic techniques. All determinations tested negative for anti-CCHFV IgG antibodies. Most of the responders were women (73.5%), and belong to the intensive care department (53.1%). In relation to other possible sources of exposures, 18.4% travelled to countries with CCHF transmission risk. No CCHF positivity was recorded among selected high-risk contacts. This highlights the importance of standard precautions which might have protected healthcare workers and care providers from CCHF infection.

Identifiants

pubmed: 32828715
pii: S1876-0341(20)30596-7
doi: 10.1016/j.jiph.2020.07.016
pii:
doi:

Substances chimiques

Immunoglobulin G 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1595-1598

Informations de copyright

Copyright © 2020 The Author(s). Published by Elsevier Ltd.. All rights reserved.

Auteurs

Pello Latasa (P)

Health Department of the Community of Madrid, Subdirectorate of Epidemiology, Madrid, Comunidad de Madrid, Spain. Electronic address: plzamalloa@gmail.com.

Fernando de Ory (F)

Centro Nacional de Microbiología, Instituto de Salud Carlos III, Majadahonda, Comunidad de Madrid, Spain.

José Ramón Arribas (JR)

La Paz - Carlos III Universitary Hospital, High Level Isolation Unit, Madrid, Comunidad de Madrid, Spain.

Maria Ángeles Sánchez-Uriz (MÁ)

Infanta Leonor Universitary Hospital, Occupational Risk Prevention Department, Madrid, Comunidad de Madrid, Spain.

Ignacio Sanchez-Arcilla (I)

Gregorio Marañón Universitary Hospital, Occupational Risk Prevention Department, Madrid, Comunidad de Madrid, Spain.

María Ordobás (M)

Health Department of the Community of Madrid, Subdirectorate of Epidemiology, Madrid, Comunidad de Madrid, Spain.

Anabel Negredo (A)

Centro Nacional de Microbiología, Instituto de Salud Carlos III, Majadahonda, Comunidad de Madrid, Spain.

Elena Trigo (E)

La Paz - Carlos III Universitary Hospital, High Level Isolation Unit, Madrid, Comunidad de Madrid, Spain.

Pilar Delgado (P)

Infanta Leonor Universitary Hospital, Occupational Risk Prevention Department, Madrid, Comunidad de Madrid, Spain.

Marco Marzola (M)

Gregorio Marañón Universitary Hospital, Occupational Risk Prevention Department, Madrid, Comunidad de Madrid, Spain.

Maria Ángeles Lopaz (MÁ)

Health Department of the Community of Madrid, Subdirectorate of Epidemiology, Madrid, Comunidad de Madrid, Spain.

María Paz Sánchez-Seco (MP)

Centro Nacional de Microbiología, Instituto de Salud Carlos III, Majadahonda, Comunidad de Madrid, Spain.

Fernando de la Calle-Prieto (F)

La Paz - Carlos III Universitary Hospital, High Level Isolation Unit, Madrid, Comunidad de Madrid, Spain.

Pilar Ferrera (P)

Infanta Leonor Universitary Hospital, Occupational Risk Prevention Department, Madrid, Comunidad de Madrid, Spain.

Elena Rodriguez (E)

Health Department of the Community of Madrid, Subdirectorate of Epidemiology, Madrid, Comunidad de Madrid, Spain.

Alejandro Martín (A)

La Paz - Carlos III Universitary Hospital, High Level Isolation Unit, Madrid, Comunidad de Madrid, Spain.

Maria Felipa Del Cerro (MF)

Infanta Leonor Universitary Hospital, Occupational Risk Prevention Department, Madrid, Comunidad de Madrid, Spain.

Esther Córdoba (E)

Health Department of the Community of Madrid, Subdirectorate of Epidemiology, Madrid, Comunidad de Madrid, Spain.

Marta Mora-Rillo (M)

La Paz - Carlos III Universitary Hospital, High Level Isolation Unit, Madrid, Comunidad de Madrid, Spain.

Maria José Esteban (MJ)

Health Department of the Community of Madrid, Subdirectorate of Epidemiology, Madrid, Comunidad de Madrid, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH